Warmly congratulate Shanghai Saierxin Biomedical Technology Co., Ltd. for moving into Zhangjiang Linfeng Pharmaceutical Science and Technology Innovation Park
Wonderful opening today!
On November 17, 2023, the opening ceremony of Shanghai Cerxin Biomedical Technology Co., Ltd. was successfully held in Zhangjiang Linfeng Pharmaceutical Science and Technology Innovation Park.
Well-known people from different industries attended the ceremony and expressed their heartfelt congratulations on the landing of Saierxin in Linfeng Pharmaceutical Science and Technology Innovation Park. The guests included Xianliang Wu, Global Senior Vice President and Managing Director of Asia Pacific of an International Company, Yuhe Chen, leader of Linfeng Park, Xinxing Zhu of Huagai Yangtze River Delta Fund, Enrico Magnani, Chief Strategy Officer of Helsen Pharmaceutical Group of Switzerland, Xing Wang, General Manager of Celanese International Trade Co., Ltd., Professor Bin Wang, Director of Shanghai Pharmaceutical Association and Vice Chairman of the Pharmacy Committee of Huashan Hospital, Lei Sun of CMB International Medical Fund, Cheng Xu, Founder and CEO of Woben Biologics, and leaders of investors in Wuxi and Hangzhou.
Board Chairman Mingqi Lu first delivered a speech to welcome the arrival of the guests, and General Manager Ya You expressed her heartfelt thanks to the investors for their trust and support, and reported the company’s milestone performance and development plan.
The guests Xianliang Wu, Yuhe Chen and Xinxing Zhu delivered speeches, affirming the achievements of the Saierxin team and expressing firm support.
The guests who were unable to attend also sent video congratulations, including Yisong Wan, professor of the Department of Immunology at the University of North Carolina, Yi Zhang, partner of Huagai Medical Yangtze River Delta Fund, Guocai Lu, president of Tianqin Biotechnology, and Lei Cai, former senior vice president of JD.com and ALS patient.
Saierxin Biomedical technology focuses on the R&D of Treg cell therapies to fill the unmet clinical needs in the fields of neurodegenerative diseases, autoimmune diseases and metabolic diseases. At present, the company’s business is progressing rapidly and the first indication is ALS. The cell process has been confirmed and the ethical committee review procedure for leukocyte collection for ALS research has been accomplished, which has laid a solid foundation for the rapid development of Investigator Initiated Trial (IIT) in China and IND in the United States.b
Saierxin has a young and passionate team and the team members are highly skilled and hard-working. Saierxin always persists in the original intention of medical people to treat diseases and save patients’lives, and is committed to keep this noble believe of “Choose one thing to be loyal to your lifelong beliefs”. Looking forward to the future, Cerxin is full of confidence.
Congratulations to Shanghai Saierxin Biomedical Technology Co., Ltd. moving to Zhangjiang Linfeng Pharmaceutical Science and Technology Innovation Park, the opening ceremony was a complete success!
Mingqi Lu and Juntao Wang led the guests to visit Zhangjiang Linfeng Pharmaceutical Science and Technology Innovation Park and the Company Building.